**Study Summary:** This study looks at a new treatment called **HZN-1116** for people with **Sjogren's Syndrome (SS)**, a condition where the body's immune system attacks its own moisture-producing glands. The study is divided into three parts: a 5-week screening period, a 48-week treatment period, and a 12-week follow-up. During treatment, participants will be randomly chosen to receive either HZN-1116 or a placebo, which is a harmless, inactive substance. **Key Points:** - The study lasts a total of 65 weeks, including all periods. - Participants will receive subcutaneous (under the skin) injections of HZN-1116 or placebo. - Participants must meet specific health criteria, such as having certain scores on disease activity scales and testing positive for specific antibodies. Before deciding to join, consider the commitment to the study's length and visits, and understand the potential risks and benefits. Eligibility criteria are strict, so make sure to discuss with your doctor if participating is right for you.